When it comes to first-line anti-vascular endothelial growth factor (VEGF) agents for the treatment of age-related macular degeneration (AMD), the overwhelming majority of retina specialists in Africa/Middle East (n = 198) and the United States (n = 740) choose bevacizumab (79.3% and 70.2%, respectively).
First-line choice in the remaining regions of the world (Asia/Pacific [n = 223], Central and South America [n = 188], and Europe [n = 298]) is aflibercept, according to results from the 2018 Global Trends in Retina survey.
In those regions where bevacizumab was the first choice, aflibercept was the second choice. In those regions where aflibercept was the first choice, bevacizumab was the second choice with the exception of Central and South America, where ranibizumab was preferred over bevacizumab.
Rishi P. Singh, MD, chairman of the International Affairs Committee of the American Society of Retina Specialists, said this year 922 members from 42 retina societies around the world participated.
A total of 15 questions were posed to the international members that were also asked in the annual Preferences and Trends (PAT) Survey, which garnered 743 responses, he said.
Not all respondents answered all questions, he said.